Acta Scientific Orthopaedics (ASOR)(ISSN: 2581-8635)

Research Article Volume 4 Issue 3

Severe Hyperuricemia, Hepatic Steatosis and Dyslipidemia in Younger Patients with Tophaceous Gout

Zheng Wuyan1, Chen Jianchun2, Lv Wanping3, Tan Wei4 and Oshmianska Nataliia1*

1Scientific Research Department, Chengdu Rheumatism Hospital, China
2Rheumatology Department 1, Chengdu Rheumatism Hospital, China
3Rheumatology Department, Chengdu Rheumatism Hospital, China
4Surgical Department, Chengdu Rheumatism Hospital, China

*Corresponding Author: Oshmianska Nataliia, Scientific Research Department, Chengdu Rheumatism Hospital, China.

Received: April 24, 2021; Published: May 11, 2021

Abstract

Introduction: Despite gout being widely known as the disease of old age, recent studies showed the rising problem of hyperuricaemia in children and young adults. Our aim was to analyze the factors influencing tophi formation in gout patients younger than 45 years old with major functional impairment of the joint.

Subjects and Methods: This study retrospectively analyzed medical records of 280 male patients between 18 and 80 years old (including 108 patients aged below 45) who were admitted in 2019-2020 with complains for major functional impairment of the joints and/or massive joint transformation and diagnosed with gout. The frequency of renal and hepatic disorders, presence of hepatic steatosis was assessed as well as lipid profile.

Results: Younger patients with disabling tophaceous gout have significantly higher serum uric acid compared to those aged above 60 and higher rate of hepatic steatosis, significantly higher triglycerides (2.62 ± 2.49 mmol/L compared to 1.75 ± 1.02) and higher total cholesterol. There was a trend for lower HDL cholesterol and higher LDL cholesterol (r = 0.116 and -0.119 respectively). Frequency of hypertriglyceridemia in younger gout patients was 39.81%, which is significantly higher compared to patients older than 60 (17.31%).

Conclusion: We found that young patients with tophaceous gout have significantly higher levels of hyperuricemia compared to patients older than 60. Rate of hepatic steatosis and dyslipidemia was also higher in younger patients, which may contribute to the development of metabolic syndrome and lead to tophi formation and major functional impairment of the joints in the very young age.

 

Keywords: Uric Acid; Hyperuricemia; Metabolic Syndrome; Gout; Hyperlipidemias; Gouty Arthritis

References

  1. Oh H., et al. “Comparisons of the Incidence and Critical Risk Factors of Metabolic Syndrome in Patients With a Rheumatic Disease or Gout”. Orthopaedic Nursing3 (2019): 201-208.
  2. Wallace KL. “Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population”. The Journal of Rheumatology 8 (2004): 1582-1587.
  3. Choi HK. “Alcohol intake and risk of incident gout in men: a prospective study”. Lancet94-17 (2004): 1277-1281.
  4. Aune D., et al. “Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies”. European Journal of Nutrition 8 (2014): 1591-1601.
  5. Kubota M. “Hyperuricemia in Children and Adolescents: Present Knowledge and Future Directions”. Journal of Nutrition and Metabolism (2019): 1-8.
  6. Zhang Q., et al. “Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese”. Clinical Rheumatology 30 (2011): 777-787.
  7. Kuwabara M., et al. “Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function”. Journal of the American Society of Nephrology 4 (2017): 330-337.
  8. Mallat SG., et al. “Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association”. Current Hypertension Reports 10 (2016): 74.
  9. Kuo CF., et al. “Comorbidities in patients with gout prior to and following diagnosis: case-control study”. Annals of the Rheumatic Diseases 75 (2016): 210-217.
  10. Zhang S., et al. “Hyperuricemia and Cardiovascular Disease”. Current Pharmaceutical Design 6 (2019): 700-709.
  11. Xu J., et al. “Associations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional study”. Lipids in Health and Disease1 (2014): 117.
  12. Lippi G., et al. “Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile”. Clinical Cardiology 33 (2010): 76-80.
  13. Alikor C., et al. “Prevalence of hyperuricaemia in a rural population of Nigerian Niger Delta region”. Nigerian Journal of Medicine 22 (2013): 187-192.
  14. Mehrpour M., et al. “Serum uric acid level in acute stroke patients”. The Medical Journal of the Islamic Republic of Iran 26 (2012): 66-72.
  15. Ni Q., et al. “Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study”. Medicine42 (2019): e17597.
  16. Kuo CF., et al. “Comorbidities in patients with gout prior to and following diagnosis: case-control study”. Annals of the Rheumatic Diseases 75 (2016): 210-217.
  17. Kuwabara M., et al. “Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan”. International Journal of Cardiology 261 (2018): 183-138.
  18. Moriyama K. “Low-density Lipoprotein Subclasses are Associated with Serum Uric Acid Levels”. Clinical Laboratory 64 (2018): 1137-1144.
  19. Li J., et al. “Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis”. The Lancet Gastroenterology and Hepatology 5 (2019): 389-398.
  20. El Ridi R and Tallima H. “Physiological functions and pathogenic potential of uric acid: A review”. Journal of Advanced Research 5 (2017): 487-493.
  21. Otani N., et al. “Effects of uric acid on vascular endothelial function from bedside to bench”. Hypertension Research 11 (2018): 923-931.
  22. Hughes MM and O'Neill LAJ. “Metabolic regulation of NLRP3”. Immunological Reviews 1 (2018): 88-98.
  23. Guo C., et al. “Cholesterol Homeostatic Regulator SCAP-SREBP2 Integrates NLRP3 Inflammasome Activation and Cholesterol Biosynthetic Signaling in Macrophages”. Immunity 5 (2018): 842-856.
  24. Pascart T., et al. “Patients With Early‐Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross‐Sectional Epidemiologic Survey”. Arthritis Care and Research 7 (2019): 986-992.

Citation

Citation: Oshmianska Nataliia., et al. “Severe Hyperuricemia, Hepatic Steatosis and Dyslipidemia in Younger Patients with Tophaceous Gout". Acta Scientific Orthopaedics 4.6 (2021): 26-31.

Copyright

Copyright: © 2021 Oshmianska Nataliia., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor0.614

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US